Ras

Cat. No.

A63645

CAS No.

2660014-14-0

KRAS G12C inhibitor 40

KRAS G12C inhibitor 40 is a selective inhibitor targeting the KRAS G12C mutation, a critical driver in various cancers. This compound disrupts the aberrant signaling pathways associated with KRAS G12C, demonstrating significant anti-cancer activity. KRAS G12C inhibitor 40 is valuable for research into the mechanisms of KRAS G12C-mediated tumorigenesis and for the development of targeted cancer therapies.

Cat. No.

A63646

CAS No.

2098509-21-6

ARS-2102

ARS-2102 is a potent covalent inhibitor of the KRAS G12C mutation, a key driver in various cancers. By selectively targeting this mutated oncogene, ARS-2102 exhibits significant anti-tumor activity, making it a valuable tool for cancer research. Its application is particularly relevant in studies focused on therapeutic strategies for KRAS-driven malignancies.

Cat. No.

A63648

CAS No.

5335-95-5

NSC 1008

NSC 1008 is a selective inhibitor of Ras converting enzyme 1 (Rce1), exhibiting an in vitro IC50 of 8.9 μM in human cells. This compound demonstrates specificity for Rce1, showing minimal inhibitory effects on human Ste24 and farnesyltransferase. NSC 1008 has low cellular toxicity and effectively induces mislocalization of EGFP-Ras from the plasma membrane in cancer cells. It serves as a valuable reagent for cancer research, facilitating studies on Rce1's role in oncogenic signaling pathways.

Cat. No.

A63649

CAS No.

27007-85-8

Spiclomazine hydrochloride

Synonyms: APY-606; Clospirazine hydrochloride

Spiclomazine hydrochloride is a KRas inhibitor recognized for its dual role as an antipsychotic and antitumor agent. This compound effectively induces apoptosis in cancer cells, making it a valuable tool in cancer research. Its action on KRas allows for exploration into the mechanisms of tumorigenesis and potential therapeutic strategies targeting KRas-driven malignancies.

Cat. No.

A63652

CAS No.

2326522-16-9

KRAS G12C inhibitor 39

KRAS G12C inhibitor 39 is a selective inhibitor targeting the KRAS G12C mutation, which is frequently associated with various cancers. This compound demonstrates significant anti-tumor activity by interfering with KRAS signaling pathways, making it a valuable tool for research into KRAS G12C-mediated oncogenesis. Its application extends to studies aimed at understanding the efficacy of targeted therapies in KRAS-driven malignancies.

Cat. No.

A63653

CAS No.

3040175-18-3

AMG410 diTFA

AMG410 diTFA is a selective pan-KRAS inhibitor targeting various KRAS mutations, including G12D, G12V, and G13D, with IC50 values ranging from 1 to 4 nM. It exhibits over 100-fold selectivity against HRAS and NRAS and acts as a dual inhibitor of GTP-bound and GDP-bound states (Kd(GDP) of 1 nM; Kd(GTP) of 22 nM). AMG410 diTFA effectively disrupts KRAS signaling irrespective of cycling state and inhibits proliferation in wild-type KRAS-amplified tumor cells. This compound is valuable for research on colorectal, pancreatic, and lung cancers.

Cat. No.

A63655

CAS No.

2253119-24-1

KRAS G12C inhibitor 47

KRAS G12C Inhibitor 47 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 of 0.172 µM. It effectively inhibits p-ERK signaling, with IC50 values of 0.046 µM in MIA PaCA-2 cells and 69.8 µM in A549 cells. This compound is a valuable tool for researching therapeutic strategies in pancreatic, colorectal, and lung cancers.

Cat. No.

A63656

CAS No.

2230873-75-1

KRAS inhibitor-15

KRAS Inhibitor-15 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting a potent IC50 of 0.954 µM. This compound demonstrates effective inhibition of phosphorylated ERK (p-ERK) with IC50 values of 2.03 µM in MIA PaCA-2 cells and >33.3 µM in A549 cells. KRAS Inhibitor-15 is suitable for investigating therapeutic strategies in pancreatic, colorectal, and lung cancers, contributing to the understanding of KRAS-driven tumorigenesis.

Cat. No.

A63657

CAS No.

2885261-76-5

KRAS G12D-IN-32

KRAS G12D-IN-32 is a selective inhibitor of the KRAS G12D mutant protein, which plays a critical role in various oncogenic pathways. This compound is instrumental for investigating the molecular mechanisms underlying adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Researchers can employ KRAS G12D-IN-32 to explore therapeutic strategies targeting KRAS mutations and to evaluate potential treatment responses in cancer models.

Cat. No.

A63659

CAS No.

2966924-23-0

KRASG12C IN-17

KRASG12C IN-17 is an orally active covalent inhibitor targeting the KRASG12C mutation. It demonstrates potent inhibitory effects on KRASG12C-mutant cancer cell lines, with IC50 values of 0.7 nM in NCI-H23 and 0.5 nM in NCI-H358. This compound irreversibly binds to KRASG12C, achieving over 96% modification efficiency in both GDP-bound and GMPPNP-bound states. KRASG12C IN-17 is valuable for research focused on KRAS-driven malignancies, particularly in the context of colorectal cancer.

Cat. No.

A63660

CAS No.

2650550-87-9

KRAS G12C inhibitor 35

KRAS G12C inhibitor 35 is a selective inhibitor targeting the KRAS G12C mutation, a driver mutation frequently associated with various cancers. This compound effectively disrupts KRAS signaling pathways, leading to inhibition of tumor cell proliferation. It serves as a valuable tool for research into KRAS G12C-mediated oncogenesis and therapeutic strategies in cancer treatment.

Cat. No.

A63662

CAS No.

2752352-90-0

KRAS G12C inhibitor 30

KRAS G12C inhibitor 30 is a selective inhibitor targeting the KRAS G12C mutation. This compound demonstrates significant anti-tumor activity by disrupting the downstream signaling pathways associated with oncogenic KRAS. It is primarily utilized in cancer research, particularly in studies focused on therapies for KRAS-driven malignancies.

Cat. No.

A63667

CAS No.

2654741-53-2

KRAS ligand 3

KRAS Ligand 3 is a target-binding ligand for KRAS that interacts with the KRAS inhibitor, enhancing its efficacy. This compound demonstrates synergistic effects in tumor growth inhibition, making it a valuable tool for research in cancer biology and therapeutic development. Its application in studying KRAS-related signaling pathways can provide insights into tumorigenesis and potential treatment strategies.

Cat. No.

A63671

CAS No.

1039455-85-0

COTI-219

COTI-219 is an orally active inhibitor of the KRAS protein, targeting its role in oncogenic signaling pathways. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. COTI-219 is utilized in studies aimed at understanding KRAS-related signaling mechanisms and evaluating therapeutic strategies for KRAS-driven tumors.

Cat. No.

A63672

CAS No.

3033236-94-8

KRAS G12C inhibitor 48

KRAS G12C Inhibitor 48 is a potent inhibitor targeting the KRAS G12C mutation, with an IC50 of 639.91 nM. This compound demonstrates significant anti-proliferative activity in various cancer cell lines, exhibiting IC50 values of 0.796 µM in H358, 6.33 µM in H23, and 16.14 µM in A549 cells. It serves as a valuable tool for research into KRAS-driven malignancies and therapeutic strategies targeting mutant KRAS.

Cat. No.

A63673

CAS No.

2914919-88-1

KRAS G12C inhibitor 59

KRAS G12C inhibitor 59 selectively targets the KRAS G12C mutant protein, inhibiting its downstream signaling pathways. This compound exhibits significant anticancer activity, making it a valuable tool for research focused on KRAS-driven malignancies. It holds potential for further exploration in therapeutic applications against cancers harboring the KRAS G12C mutation.

Cat. No.

A63674

CAS No.

2735721-00-1

KRAS G12C inhibitor 23

KRAS G12C inhibitor 23 is a selective inhibitor targeting the KRAS G12C mutation. It effectively inhibits H358 cells with an IC50 value of 491 nM, demonstrating its potential in cancer research. This compound is primarily utilized in studies focused on KRAS-driven cancers for therapeutic development and efficacy evaluation.

Cat. No.

A63675

CAS No.

2734060-73-0

KRAS G12C inhibitor 25

KRAS G12C Inhibitor 25 primarily targets the KRAS G12C mutant by inhibiting the SOS1-assisted GDP/GTP exchange activity, demonstrating an IC50 of 0.48 nM. This compound has potential applications in therapeutic research aimed at KRAS-driven cancers, providing a valuable tool for studying the role of KRAS mutations in tumorigenesis and evaluating potential treatment strategies.

Cat. No.

A63676

CAS No.

2763155-39-9

KRAS G12D inhibitor 15

KRAS G12D Inhibitor 15 is a selective inhibitor targeting the KRAS G12D mutation, a critical player in various cancer pathways. This compound demonstrates significant potential in studies related to cancer progression and metastasis. Additionally, KRAS G12D Inhibitor 15 features an alkyne moiety, enabling its use in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, making it a valuable tool for chemical biology applications.

Cat. No.

A63677

CAS No.

3026014-12-7

pan-KRAS-IN-17

pan-KRAS-IN-17 is a potent inhibitor targeting pan-KRAS. This compound effectively disrupts KRAS signaling pathways, demonstrating significant activity in various cancer models characterized by KRAS mutations. It is a valuable tool for research into KRAS-driven malignancies and for investigating therapeutic approaches aimed at inhibiting malignant cell proliferation and survival.

Cat. No.

A63678

CAS No.

2648551-72-6

KRAS G12D inhibitor 11

KRAS G12D inhibitor 11 is a potent inhibitor targeting the KRAS G12D mutation, a critical driver of various cancers. This compound interferes with the signaling pathways mediated by the Ras family of proteins, which are essential for cellular proliferation and survival. KRAS G12D inhibitor 11 is applicable in research focused on KRAS G12D-mediated oncogenesis and therapeutic development for related malignancies.

Cat. No.

A63679

CAS No.

2761279-63-2

StRIP16

StRIP16 is a bioavailable analogue of StRIP3 that functions as a Ras inhibitor. This double-stapled peptide exhibits high specificity for Rab8a GTPase, with a dissociation constant (Kd) of 12.7 μM. StRIP16 is utilized in research to investigate the role of Rab8a in cellular signaling pathways and its implications in various cancer models.

Cat. No.

A63682

CAS No.

149957-14-2

ISIS 2503

ISIS 2503 is a 20-mer antisense oligonucleotide specifically designed to inhibit the expression of Ha-Ras. By targeting the mRNA of Ha-Ras, ISIS 2503 effectively reduces its protein levels, thereby modulating downstream signaling pathways associated with cell proliferation and survival. This reagent is valuable for research applications focused on cancer biology and the study of oncogenic signaling mechanisms.

Cat. No.

A63683

CAS No.

2875116-29-1

pan-KRAS-IN-3

pan-KRAS-IN-3 is a pan-KRAS inhibitor designed to target and inhibit KRAS signaling pathways, which are commonly implicated in various cancers. This compound serves as a useful tool for cancer research by effectively blocking KRAS activity, thereby offering insights into tumor biology and potential therapeutic strategies. Additionally, pan-KRAS-IN-3 features an alkyne group enabling its participation in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating the development of novel chemical probes and conjugates in experimental studies.

Cat. No.

A63684

CAS No.

2833695-47-7

KRAS G12D inhibitor 19

KRAS G12D inhibitor 19 is a selective inhibitor targeting the KRAS G12D mutant protein, which plays a pivotal role in driving oncogenic signaling pathways in various cancers. This compound exhibits significant anti-proliferative activity against KRAS G12D-driven tumor cell lines. It serves as a valuable tool in cancer research, particularly for studying the efficacy of KRAS-targeted therapies and understanding the mechanistic pathways involved in KRAS-related malignancies.